reduction in incidence of early fatal complications of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in hodgkin lymphoma patients

Clicks: 363
ID: 162439
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 24 articles by views in basic and clinical neuroscience

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract

Traditionally, the concern of fatal complication is a major obstacle to transfer patients with unfavorable course of Hodgkin’s lymphoma to
national transplantation centers. Early mortality after high-dose chemotherapy with autologous hematopoietic stem cell transplantation
(HSCT) in the Russia, Ukraine and Belarus was assessed in this retrospective multicenter study.


Patients and methods. The study included 372 patients with unfavorable course of Hodgkin’s lymphoma received HSCT between 01.1990
and 06.2013: 35.5 % patients with primary resistance, 30.6 % with early relapse, 33.1 % with late relapse and 0.8 % during consolidation of
first complete remission.


Results. During first 100 days after HSCT died 14 (3.8 %) patients, during first year – 31 (8.4 %) patients. During the study period a significant decrease in the 100-day and 1-year mortality rate was observed (p < 0.0001 for both). Among patients received HSCT in 1990–
1995, 1996–2000, 2001–2005 and 2006–2013 the 100-day mortality was 19.4 %, 6.3 %, 1.1 % and 0.6 %, respectively. 1-year mortality for the same intervals was 32.3 %, 14.7 %, 4.5 % and 1.9 %, respectively.

Conclusions. Currently HSCT in patients with unfavorable course of Hodgkin's lymphoma in national transplant centers, accompanied by an extremely low risk of fatal toxicity.

Reference Key
zhukov2014onkogematologireduction Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;N. V. Zhukov;A. L. Uss;N. F. Milanovich;V. V. Ptushkin;B. V. Afanasyev;N. B. Mikhaylova;V. B. Larionova;E. A. Demina;E. E. Karamanesht;N. G. Tyurina;O. A. Pavlova;A. G. Rumyantsev;A. D. Kaprin
Journal basic and clinical neuroscience
Year 2014
DOI
DOI not found
URL
http://oncohematology.abvpress.ru/index.php/ongm/article/view/24
Keywords
hematopoietic stem cell transplantation hodgkin lymphoma

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.